Ed­i­tas founder Ka­trine Bosley abrupt­ly steps aside from the helm, just ahead of his­toric CRISPR move

For close to 5 years now Ka­trine Bosley has led Ed­i­tas Med­i­cine $ED­IT through good times and bad, right to the thresh­old of dos­ing its first pa­tient in the pre­mier clin­i­cal study for its ground­break­ing gene-edit­ing tech.

But she’s not tak­ing the next step with the team.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER